Progress in biomedical research depends on credible evidence. When results cannot be replicated, programs can lose momentum, funding, and confidence in the data. Reproducibility, therefore, is a scientific principle and practical safeguard that protects the time, resources, and credibility of investigators and their institutions [1, 2].
A global survey of more than 1,500 scientists found that over 70 percent had failed to reproduce another researcher’s findings, and more than 50 percent had been unable to reproduce their own [1]. Recent analyses focused on antibodies argue that poorly characterized reagents are a major contributor to this problem and call for a substantive shift in how antibodies are evaluated, shared, and reported [3, 4].
The Antibody Crisis
Among the most significant sources of experimental variability in life science research are antibodies used for detection, quantification, and localization of proteins [3]. Recent reviews document that many widely used antibodies lack rigorous characterization, leading to non-specific binding, off-target recognition, and misleading or incorrect biological conclusions in both basic and translational studies [3, 4].
When an antibody fails to recognize its intended target or binds additional proteins in complex samples, the result is wasted specimens, lost staff time, and figures that can propagate artifacts through the literature [3, 5].
Where Reproducibility Really Begins
Reproducibility begins when investigators specify the materials and controls that will support their experimental design. International working groups have outlined a multi-pillar framework for antibody validation that includes genetic knockout or knockdown controls, orthogonal strategies using independent assays, independent-antibody approaches, recombinant expression or tagging strategies, and immunocapture followed by mass spectrometry [6].
These pillars provide converging lines of evidence that an antibody recognizes its intended epitope with sufficient selectivity and sensitivity in the relevant matrix, species, and application [6, 3].
Despite the availability of this framework, recent evaluations conclude that only a small fraction of commercial antibodies are supported by comprehensive, multi-pillar characterization, while most are documented with limited in-house data in one assay, often without genetic controls or orthogonal confirmation [3, 4].
In practice, this shifts the most critical characterization experiments into individual laboratories, which frequently encounter failures after a project is underway, a core facility has committed instrument time, or reviewers scrutinize the validation sections of a manuscript or grant [3, 4].
The Scale and Cost of Incomplete Validation
The global catalog of research antibodies now contains several million products across numerous suppliers, clones, and formats [4]. Large-scale assessments using standardized pipelines, including knockout-based validation across multiple applications, have shown that a substantial fraction of tested commercial antibodies fail to meet minimal performance criteria in Western blotting, immunofluorescence, and immunoprecipitation [7].
In some datasets, fewer than half of the antibodies recommended for specific applications consistently detect their intended target under defined conditions, even when they are widely cited in the literature [7].
These failures have quantifiable scientific and operational costs. Each non-specific band or irreproducible staining pattern can trigger repeat experiments, protocol revisions, and additional rounds of troubleshooting, consuming reagents, animal cohorts, cell lines, and core facility time that were originally budgeted for new experiments [4, 7]. For early-career investigators, a single irreproducible dataset linked to an under-validated antibody can delay key submissions and affect fellowship or grant competitiveness in the next cycle [3, 4].
Raising the Bar for Characterization and Reporting
The research community is responding with stronger expectations for reagent transparency and documentation. Recent guidance emphasizes that antibody use should be supported by application-specific validation data, clear descriptions of experimental conditions, and unambiguous identification of each reagent through catalog numbers and resource identifiers [4, 5].
These measures are intended to ensure that every antibody in a figure or table can be uniquely traced back to its source and associated validation evidence, allowing others to assess whether the reagent is appropriate for the reported conclusions [5].
However, guidelines alone are insufficient without corresponding investment in characterization by suppliers. Robust antibody validation requires systematic incorporation of genetic perturbation controls, orthogonal assays, and well-defined positive and negative biological samples into the development pipeline [3, 4, 6].
Antibody Quality as a Strategic Choice
Selecting well-characterized antibodies is not a minor purchasing preference; it is a strategic decision that shapes the interpretability and longevity of experimental results. Antibodies supported by multi-pillar characterization reduce the likelihood that key findings rest on undetected cross-reactivity or lot-to-lot drift and lower the probability that critical datasets will require extensive repetition or be challenged during peer review [3, 6, 7].
Programs that incorporate rigorous antibody selection are better positioned to publish reproducible findings, respond to reviewer requests and maintain credibility with collaborators and oversight bodies [3, 4, 5]. Reproducibility, when supported by antibody characterization enables what investigators, institutions, and funders all require: data that can be re-analysed, extended, and translated without repeated concern that a fundamental detection reagent was the weak link in the experimental chain [3, 4, 7].
Partnering to Support Reproducibility
Consult with the Antibody Solutions team at Fortis Life Sciences, our antibodies are manufactured in-house and validated per our 6 Pillars of Validation framework.
Ask us how we can improve the technical rigor of your research program.
Resources
- Baker, M. (2016). 1,500 scientists lift the lid on reproducibility. Nature, 533(7604), 452–454. National Academies of Sciences, Engineering, and Medicine. (2019). Reproducibility and replicability in science. National Academies Press.
- Kahn, R. A., & Laflamme, C. (2024). Antibody characterization is critical to enhance reproducibility in biomedical research. eLife, 13, e100211.
- Biddle, M., Stylianou, P., et al. (2024). Improving the integrity and reproducibility of research that uses antibodies: A technical, data sharing, behavioral and policy challenge. mAbs, 16(1), 2323706.
- Bandrowski, A., Brush, M. H., Grethe, J. S., Haendel, M. A., Kennedy, D. N., Hill, S., et al. (2016). The Resource Identification Initiative: A cultural shift in publishing. Journal of Comparative Neurology, 524(1), 8–22.
- Uhlén, M., Bandrowski, A., Carr, S., Edwards, A., Ellenberg, J., Lundberg, E., et al. (2016). A proposal for validation of antibodies. Nature Methods, 13(10), 823–827.
- Ayoubi, R., Laflamme, C., Shlaifer, I., Droit, A., Krockow, E. M., Ruddy, D., Virk, H. S., Kahn, R. A., & Chambers, C. R. (2023). Scaling of an antibody validation procedure enables quantification of antibody performance at the proteome scale. eLife, 12, e91645.
- Fortis Life Sciences. Antibody validation.